Arbutus Biopharma (ABUS) vs ProKidney (PROK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Arbutus Biopharma (ABUS) has outperformed ProKidney (PROK) over the past year, gaining 0.0% versus a loss of 47.0%. Over five years, ABUS leads with a +5.1% price change compared with -84.1% for PROK. Arbutus Biopharma is the larger company by market cap ($657.6 million vs $626.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABUS | PROK |
|---|---|---|
| Share price | $4.29 | $1.57 |
| Market cap | $657.55M | $626.72M |
| 1-day change | -4.24% | -1.88% |
| YTD return | -10.81% | -29.91% |
| 1-year return | 0.00% | -46.96% |
| 5-year return | +5.15% | -84.09% |
| P/E ratio (TTM) | 5.43 | — |
| EPS (TTM) | $0.79 | $-0.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.45 | $3.48 |
| 52-week low | $3.50 | $1.30 |
| Distance from 52-week high | -21.28% | -54.89% |
| Analyst consensus | none | none |
| Avg. price target upside | +24.71% | +298.09% |
| Average volume | 4.68M | 1.30M |
| Shares outstanding | 153.28M | 208.93M |
| Employees | 19 | 231 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABUS has outperformed PROK by 47.0 percentage points over the past year.
About Arbutus Biopharma
ABUS stock →Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
About ProKidney
PROK stock →ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 231 employees
ABUS vs PROK FAQ
Which is bigger, Arbutus Biopharma or ProKidney?
Arbutus Biopharma (ABUS) is larger, with a market capitalization of $657.55M compared with $626.72M for ProKidney (PROK).
Which stock has performed better over the past year, ABUS or PROK?
ABUS returned 0.00% over the past 12 months, compared with -46.96% for PROK (price return, excluding dividends). Past performance does not predict future results.
Are Arbutus Biopharma and ProKidney in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Arbutus Biopharma and Biotechnology: Biological Products (No Diagnostic Substances) for ProKidney.